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Changes in distribution policies have increased median MELD at transplant with recipients requiring increasing intensive care
perioperatively. We aimed to evaluate association of preoperative variables with postoperative respiratory failure (PRF)/increased
intensive care unit length of stay (ICU LOS)/short-term survival in a high MELD cohort undergoing liver transplant (LT).
Retrospective analysis identified cases of PRF and increased ICU LOS with recipient, donor, and surgical variables examined.
Variables were entered into regression with end points of PRF and ICU LOS > 3 days. 164 recipients were examined: 41 (25.0%)
experienced PRF and 74 (45.1%) prolonged ICULOS. Significant predictors of PRFwith univariate analysis: BMI> 30, pretransplant
MELD, preoperative respiratory failure, LVEF < 50%, FVC < 80%, intraoperative transfusion > 6 units, warm ischemic time >
4 minutes, and cold ischemic time > 240 minutes. On multivariate analysis, only pretransplant MELD predicted PRF (OR 1.14,
𝑝 = 0.01). Significant predictors of prolonged ICU LOS with univariate analysis are as follows: pretransplant MELD, FVC < 80%,
FEV1 < 80%, deceased donor, and cold ischemic time > 240 minutes. Onmultivariate analysis, only pretransplant MELD predicted
prolonged ICU LOS (OR 1.28, 𝑝 < 0.001). One-year survival among cohorts with PRF and increased ICU LOS was similar to
subjects without. Pretransplant MELD is a robust predictor of PRF and ICU LOS. Higher MELDs at LT are expected to increase
need for ICU utilization and modify expectations for recovery in the immediate postoperative period.
1. Introduction
Liver transplantation (LT) is a lifesaving procedure for
patients with end stage liver disease and hepatocellular
carcinoma. Recent policy changes aimed at optimizing organ
distribution have increased the percentage of transplants
performed for recipients with Model for End Stage Liver
Disease (MELD) scores greater than 35 [1, 2]. As the trend
toward higher MELD scores at the time of LT continues,
recipients will require increasingly advanced and intensive
care as a bridge to surgery. Recent studies have suggested
that increased ICU utilization and preoperative respiratory
failure are not contraindications to liver transplantation, with
satisfactory long-term outcomes achievable through proper
patient selection [3]. However, risk factors for postopera-
tive respiratory failure (PRF) and increased ICU utilization
immediately after LT remain poorly defined.
PRF, defined as unplanned intubation or inability to
extubate within 48 hours after surgery, is a common surgical
complication [4]. In the general surgical population, PRF
is associated with increased 30-day morality, length of stay
(LOS) in the ICU, health-care expenditure, and decreased
long-term survival [5–7]. In this context, risk factors pre-
dictive of PRF include type of surgery, emergency status,
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dependent functional status, preoperative sepsis, higher
American Society ofAnesthesiologists (ASA) class, acute kid-
ney injury, and low albumin. These factors are of decreased
predictive utility in the LT candidate population in which
low albumin, functional dependence, and high ASA class are
common; and active, uncontrolled sepsis may temporarily
inactivate status on the wait list.
Previous studies identifying risk factors for PRF in liver
transplant patients have had conflicting results and report
experience in recipients with relatively low biologic MELD
scores at the time of LT surgery, ranging from 15 to 20 [8–10].
The purpose of this investigationwas to evaluate preoperative
donor, host, cardiopulmonary, and surgical variables and
their association with incidence of PRF and prolonged ICU
LOS in a cohort of LT recipients from United Network for
Organ Sharing (UNOS) Region 5.
2. Methods
2.1. Study Design. This was a retrospective analysis of 164
consecutive patients undergoing LT over a 3-year period
(2011–2014) at Banner University Medical Center in Phoenix,
Arizona. After institutional review board approval, inpatient
and outpatient medical records were examined with clinical
endpoints and variables of interest tabulated.
2.2. Clinical Endpoints. Primary clinical endpoints under
investigation included postoperative respiratory failure and
increased ICU LOS. Postoperative respiratory failure was
defined as unplanned reintubation or inability to extubate
within 48 hours after LT surgery. The average ICU LOS after
transplant in our institution was 5.7 days with median of
3 days. Increased ICU LOS was defined as a length of stay
greater than 3 days (centermedian). Short-term survival after
transplantationwasmeasured in days from transplantation to
1 year after transplantation.
2.3. Variables Predicting Postoperative Respiratory Failure and
Prolonged ICU Length of Stay. Pre-LT host demographic
variables included body mass index (BMI), age, smoking
status, concomitant renal insufficiency, etiology of cirrhosis,
pretransplant biologic MELD, and recipient cytomegalovirus
(CMV) status. Pre-LT cardiopulmonary variables included
LVEF, diastolic dysfunction, FEV1 < 80% predicted, FVC <
80% predicted, and FEV1/FVC < 80% predicted. Trans-
plant surgery related variables included donor gender,
warm ischemic time > 40 minutes, packed red blood cell
transfusion > 6 units (cohort median), and cold ischemic
time > 240 minutes.
2.4. Statistical Analysis. Apower analysis usingG∗Powerwas
conducted for binary logistic regression at a 0.05 significance
level, Pr(𝑌 = 1 | 𝑋 = 1)H0 of 0.2, effect size of 1.8, and a given
sample size of 164 to compute achieved power. Descriptive
statistics for demographic variables were performed. Baseline
demographics were tabulated for the entire population for
subgroups with PRF and ICU LOS > 3 days. Binary logistic
regression was conducted to predict risk factors for PRF and
ICU LOS > 3 days independently. Dependent variables (PRF
and ICU LOS) were dichotomous. PRF was dichotomized
into 0 and 1, indicating the absence and presence of PRF,
respectively. ICU LOS was dichotomized into 0, indicating a
LOS less than or equal to 3 days, and 1, indicating LOS greater
than 3 days. We initially employed univariate regression
analysis to predict potential risk factors for PRF and ICU
LOS. Variables with 𝑝 < 0.25 from the univariate logistic
regression were then incorporated into multivariate logistic
regression to determine final risk factors for PRF and ICU
LOS.
Nagelkerke 𝑅 squares were used for the model summary.
Wald statistics were used to assess the contribution of
predictors in a given model. Hosmer and Lemeshow tests
were used to measure goodness-of-fit of the data in a given
model. A nonsignificant chi-square value indicated a good
model fit when there was little unexplained variance in the
model. Survival frequencies at 1 year were compared between
groups using chi-square analysis. SPSS software (Statistical
Product and Services Solutions, version 22, Chicago, IL,USA)
was used for statistical analyses.
3. Results
3.1. Respiratory Failure and ICU Length of Stay. A total of
164 patients were included in the study (Table 1). Of the total
population, 41 (25.0%) experienced postoperative respiratory
failure. Seventy-four (45.1%) patients had an ICULOS greater
than the median of 3 days and were considered to have a
prolonged ICU LOS. Overall one-year survival was 90.2%.
The most common indications for LT included hepatitis
C with 69 patients (42.1%), followed by metabolic causes,
including alcohol abuse, with 40 patients (24.4%). Fifteen
(9.1%) patients had preoperative respiratory failure requiring
intubation prior to transplant. Average biologic pretransplant
MELD was 31.4 ± 7.3.
Baseline cardiopulmonary data was similar between PRF
and the increased ICULOS groups. No significant differences
existed between hospital admission status and need for renal
replacement therapy immediately prior to transplant. On
echocardiograms, diastolic dysfunction (29.2%) was themost
commonly seen abnormality, followed by left ventricular
systolic dysfunction with an ejection fraction < 50% (1.8%).
Restrictive lung patterns (frequency of FVC < 80% = 12.8%)
were relatively more common than obstructive ones (fre-
quency of FEV1/FVC< 80%= 5.5%).The incidence of FEV1 <
50% was 3 (1.8%).
3.2. Predictors of Prolonged Respiratory Failure. Significant
predictors of postoperative respiratory failure on univariate
analysis (Table 2) included BMI > 30 (OR 1.02, 𝑝 = 0.05),
pretransplant MELD (OR 1.18, 𝑝 < 0.01), preoperative
respiratory failure (OR 11.28, 𝑝 < 0.01), LVEF < 50% (OR
6.26, 𝑝 = 0.14), FVC < 80% (OR 2.18, 𝑝 = 0.15), packed
red blood cell transfusion > 6 units intraoperatively (OR 1.15,
𝑝 = 0.04), warm ischemic time > 40 (OR 0.62, 𝑝 = 0.18),
and cold ischemic time > 240 (OR 3.77, 𝑝 = 0.02). On
multivariate analysis, only pretransplant MELDwas found to
predict PRF (OR 1.14, 𝑝 < 0.01) after eliminating variables
which showed high multicollinearity (Table 2, 𝑅2 = 0.333;
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Table 1: Baseline demographic characteristics.
Demographic variables Total population (𝑛 = 164) PRF (𝑛 = 41) ICU LOS > 3 days (𝑛 = 74)
Age at transplant (Years ± SD) 56.1 ± 8.7 55.3 ± 9.1 55.4 ± 8.9
Inpatient status immediately prior to transplant 50 (30.4%) 13 (31.7%) 14 (18.9%)
Gender (Male) 105 (64.0%) 24 (58.5%) 44 (59.6%)
BMI (kg/m2 ± SD) 28.3 ± 5.6 28.7 ± 6.3 28.4 ± 6.1
Large volume ascites 23 (14.0%) 5 (12.2%) 11 (14.9%)
Pretransplant serum albumin (g/dl) 2.3 ± 0.7 2.4 ± 0.8 2.1 ± 0.5
Pretransplant need for renal replacement therapy 65 (39.6%) 14 (34.1%) 31 (41.8%)
Pretransplant biologic MELD ± SD 31.4 ± 7.3 36.4 ± 5.8 35.8 ± 5.5
Preoperative respiratory failure 15 (9.1%) 11 (26.8%) 15 (20.3%)
Smoking history 51 (30.1%) 15 (36.6%) 21 (28.4%)
Concurrent kidney transplant 11 (6.7%) 3 (7.3%) 5 (6.7%)
Primary indication
Hepatitis C 69 (42.1%) 10 (24.3%) 20 (27.0%)
Metabolic 27 (16.5%) 8 (19.5%) 12 (16.2%)
Any with HCC 11 (6.7%) 2 (4.9%) 8 (10.8%)
Autoimmune 40 (24.4%) 14 (34.1%) 22 (29.7%)
Nonalcoholic steatohepatitis 19 (11.6%) 8 (19.5%) 13 (17.6%)
Echocardiography
LVEF < 50% 3 (1.8%) 2 (4.9%) 2 (2.7%)
Diastolic dysfunction 48 (29.2%) 11 (26.8%) 11 (14.9%)
Pulmonary function testing
FEV1/FVC < 80% 9 (5.5%) 2 (4.9%) 2 (2.7%)
FVC < 80% 21 (12.8%) 7 (17.1%) 7 (9.4%)
FEV1 < 80% 23 (14.0%) 9 (21.9%) 9 (12.1%)
Donor gender (male) 105 (64.0%) 26 (63.4%) 49 (66.2%)
Donor CMV positive 104 (63.4%) 24 (58.5%) 45 (60.8%)
Warm ischemic time (minutes ± SD) 32 ± 21 28 ± 15 30 ± 15
Cold ischemic time (minutes ± SD) 198 ± 69 221 ± 79 205 ± 72
Packed red blood cell transfusion > 6 units 71 (45%) 21 (51.2%) 38 (51.3%)
PRF: postoperative respiratory failure; ICU: intensive care unit; LOS: length of stay; SD: standard deviation; BMI: body mass index; MELD: Model for End
Stage Liver Disease; EF: ejection fraction; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; CMV: cytomegalovirus.
chi-square = 8.081, 𝑝 = 0.426). The average pretransplant
MELD in patients with PRF was 36.4, which was significantly
higher than the group without PRF (29.8, 𝑝 < 0.001).
3.3. Predictors of ICU Length of Stay. Significant predictors
of an ICU LOS greater than 3 days (Table 3) on univariate
analysis included pretransplant MELD (OR 1.25, 𝑝 < 0.01),
heart failure (OR 1.41, 𝑝 = 0.06), diastolic dysfunction (OR
2.01, 𝑝 = 0.05), FVC < 80% (OR 2.62, 𝑝 = 0.05), FEV1 < 80%
(OR 3.76, 𝑝 < 0.01), deceased donor (OR 1.95, 𝑝 = 0.07),
and cold ischemic time > 240 (OR 2.34, 𝑝 = 0.04). All of the
patients with preoperative respiratory failure experienced an
ICU LOS greater than 3 days, and the variable could not be
carried forward into multivariate analysis.
On multivariate analysis, pretransplant MELD, with an
OR of 1.28, was the strongest predictor of an ICU LOS greater
than three days (𝑝 < 0.001). Restrictive PFTs defined by
FVC < 80% were protective of an increased ICU LOS (OR
0.04, 𝑝 = 0.04), except those with more severe forms of
lung disease associated with a reduction of FEV1 < 80%
(OR 36.88, 𝑝 = 0.02) (𝑅2 = 0.516; chi-square = 5.729,
𝑝 = 0.678). The multivariate model for increased ICU
LOS was then systematically repeated with all permutations
of one variable for heart failure (either all heart failure or
diastolic dysfunction) and one variable for lung restriction
(either FVC < 80% or FEV1 < 80%) while retaining the rest
of the variables. In these models, pretransplant MELD was
consistently a significant predictor of an increased ICU LOS.
However, neither heart failure nor the restrictive lung disease
variables were significant predictors.
3.4. Survival. Overall (𝑛 = 164) 1-year survival after ortho-
topic liver transplantation was 90.2% in the cohort. Although
there was a trend toward lower 1-year survival in those with
PRF compared to those without (81.2% versus 91.2%, 𝑝 =
0.36) this was not significant. In those with prolonged ICU
length of stay survival at 1 year was also similar at 87.5% versus
92.4% (𝑝 = 0.30).
4. Discussion
Liver transplantation, owing to its scarcity, requires unique
and extensive cardiopulmonary risk stratification. Guidelines
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Table 2: Univariate and multivariate analysis of PRF.
PRF (𝑛 = 41)
Univariate Multivariate
Variable 𝛽 OR 𝑝 95% CI 𝛽 OR 𝑝 95% CI
Age at transplant > 65 years −0.07 0.93 0.88 0.93–2.36
Inpatient status prior to transplant 0.05 1.09 0.88 0.41–2.39
BMI > 30 kg/m2 0.02 1.02 0.05 0.96–1.07 0.07 1.07 0.16 0.97–1.19
Large volume ascites −0.19 0.83 0.72 0.29–2.38
Pretransplant MELD 0.16 1.18 <0.01 1.10–1.26 0.13 1.14 <0.01 1.03–1.25
Preoperative respiratory failure 2.42 11.28 <0.01 3.37–37.89 1.96 7.06 0.06 0.97–51.57
Smoking history positive 0.38 1.46 0.32 0.69–3.07
Kidney transplant 0.14 1.15 0.84 0.30–4.54
Heart failure 0.03 1.03 0.90 0.69–1.52
Diastolic dysfunction 0.04 1.04 0.92 0.47–2.31
Left ventricular EF < 50% 1.85 6.26 0.14 0.55–71.00
FEV1/FVC −0.03 0.98 0.98 0.19–5.03
FVC < 80% 0.79 2.18 0.15 0.76–6.22 −0.33 0.72 0.64 0.18–2.91
FEV1 < 80% 1.03 2.08 0.35 1.04–7.44
Donor gender (male) −0.02 0.98 0.95 0.47–2.04
Deceased (versus living) donor 0.14 1.15 0.75 0.51–2.57
Warm ischemic time > 40 minutes −0.49 0.62 0.18 0.19–2.13 −0.06 0.94 0.93 0.22–4.03
Cold ischemic time > 240 minutes 1.33 3.77 0.02 1.35–6.37 0.82 2.28 0.26 0.55–9.40
Recipient CMV IgG 0.07 1.07 0.86 0.49–2.33
Packed red blood cell transfusion > 6 units 0.09 1.15 0.04 0.96–1.07 0.09 1.11 0.18 0.97–1.19
PRF: postoperative respiratory failure; ICU: intensive care unit; LOS: length of stay; SD: standard deviation; BMI: body mass index; MELD: Model for End
Stage Liver Disease; EF: ejection fraction; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; CMV: cytomegalovirus.
Table 3: Univariate and multivariate analysis of ICU LOS.
ICU LOS > 3 days (𝑛 = 74)
Univariate Multivariate
Variable 𝛽 OR 𝑝 95% CI 𝛽 OR 𝑝 95% CI
Age at transplant > 65 years −0.20 0.82 0.62 0.37–1.83
Inpatient status prior to transplant 0.65 1.95 0.04 0.100–4.04 −2.40 0.11 0.45 0.01–30.04
BMI > 30 kg/m2 0.01 1.01 0.77 0.95–1.07
Large volume ascites 0.20 1.22 0.66 0.50–2.94
Pretransplant MELD 0.22 1.25 <0.01 1.16–1.33 0.25 1.28 0.00 1.15–1.42
Preoperative respiratory failure NA NA NA NA
Smoking history positive −0.12 0.89 0.73 0.46–1.73
Kidney transplant 0.03 1.03 0.97 0.30–3.51
Heart failure 0.34 1.41 0.06 0.99–2.00 1.43 4.16 0.34 0.23–76.36
Diastolic dysfunction 0.70 2.01 0.05 0.100–4.04 −2.49 0.08 0.40 0.01–28.04
Left ventricular EF < 50% 0.91 2.49 0.46 0.22–27.98
FEV1/FVC 0.61 1.83 0.39 0.47–7.20
FVC < 80% 0.69 2.62 0.05 1.01–6.79 −3.31 0.04 0.04 0.01–0.86
FEV1 < 80% 1.32 3.76 <0.01 1.46–9.70 3.61 36.88 0.02 1.89–719.14
Donor gender (male) −0.25 0.78 0.45 0.41–1.48
Deceased (versus living) donor 0.67 1.95 0.07 0.96–3.96 0.53 1.70 0.37 0.54–5.41
Warm ischemic time > 40 minutes −0.24 0.79 0.45 0.17–1.72
Cold ischemic time > 240 minutes 0.85 2.34 0.04 1.08–3.60 1.69 5.39 0.07 0.85–34.12
Recipient CMV IgG −0.16 0.85 0.64 0.44–1.66
Packed red blood cell transfusion > 6 units 0.07 1.54 0.49 0.75–1.27
OR: odds ratio; 95% CI: 95% confidence interval; BMI: body mass index; MELD: Model for End Stage Liver Disease; EF: ejection fraction; FEV1: forced
expiratory volume in one second; FVC: forced vital capacity; CMV: cytomegalovirus.
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from the American Association for the Study of Liver Disease
recommend cardiopulmonary risk stratification with screen-
ing for coronary artery disease, portopulmonary hyperten-
sion, and hepatopulmonary syndrome prior to liver trans-
plantation [11]. Work-up of the aforementioned includes
contrast-enhanced echocardiography and pulmonary func-
tion testing at a minimum. Patients with angiographically
assessed and advanced coronary artery disease or primary
lung disease may be excluded from transplantation.
PRF is a common complication after surgery and occurs
after approximately 3% of surgical cases with general anes-
thesia [6]. Previous studies have estimated total postoperative
pulmonary complications after liver transplantation to be
close as high as 50% [8]. Factors such as higher incidence
of pleural effusion, severe restrictive pulmonary function
patterns, protein calorie malnutrition, and increased need for
perioperative blood transfusions may predispose to higher
rates of pulmonary complications [12]. In the general surgical
population, PRF has been associated with an increased ICU
LOS, 30-day mortality, and long-term mortality [4–7].
Several studies have examined predictors of pulmonary
complications after liver transplant. Most of studies exam-
ine a composite of postoperative pulmonary complications,
including pulmonary thromboembolism, atelectasis, pneu-
monia, and pleural effusion. Levesque et al. found restrictive
lung patterns (OR 3.14, 𝑝 = 0.002) and elevated INR (OR
4.95,𝑝 = 0.0004) to be predictive of postoperative pulmonary
complications [8]. Hong et al. found elevated bilirubin (OR
2.2, 𝑝 = 0.031) and a history of acute rejection (OR 5.4, 𝑝 =
0.001) to be predictive of pulmonary complications within
one year, though of the complications 74% (50/67) were
pleural effusions seen on chest roentgenograms [10]. One
study examined PRF as defined in our study, Huang et al.,
and identified diabetes (OR 7.55, 𝑝 = 0.001), pretransplant
respiratory failure (OR 68.85, 𝑝 = 0.002), renal insufficiency
(OR 5.93, 𝑝 = 0.003), liver grafts from deceased donors
(OR 3.44, 𝑝 = 0.006), and use of a molecular adsorbent
recirculating system (OR 14.09, 𝑝 = 0.024) to be predictive
of PRF [12].
Long-term clinical consequences of PRF and increased
ICU LOS after LT continue to be explored. Some studies
have found no link between PRF and increased ICU LOS and
mortality. Levesque et al. found no association between PRF
and mortality in patients with an average MELD of 14.8 [8].
Oberkofler et al. found no association between an increased
ICU LOS and mortality in patients with an average MELD
of 19.5 [9]. However, in agreement with the general surgical
literature, Hong et al. found an association between PRF and
mortality by Kaplan Meier analysis at one year (𝑝 < 0.005)
though an average MELD score was not provided [10]. This
was also seen by Bozbas et al., who found that a postoperative
pulmonary complication (predominantly pneumonia and
pleural effusion) was associated with one-year mortality,
which was more pronounced in patients with a positive deep
tracheal aspirate culture (𝑝 = 0.001) [13].
In this investigation, MELD was the only predictor of
PRF and an ICU LOS > 3 days. This is consistent with
previous studies, which has found various components such
as high INR [8], renal failure [12], and elevated bilirubin
[10] to be predictive of PRF. Our study had a markedly
higher MELD score that previously reported with an average
MELD of 30.0. Rates of PRF at 25% were slightly higher
than previously reported (17% in Levesque, with an average
MELD 14.8) [8]. Of interest, no cardiopulmonary variable
was found to be predictive of PRF. Moderate to severe lung
diseases causing a reduction of FEV1 were associated with
an increased ICU LOS. However, the presence of restrictive
lung disease itself (perhaps as a consequence of ascites)
was not predictive of either PRF or an increased ICU LOS.
Furthermore, the necessity for prolonged intubation before
or after transplantation is not associated with decreased one-
year survival.
As the average MELD for liver transplant continues to
increase [1, 2], incidence of pre- and postoperative com-
plications will continue to rise. These peritransplant com-
plications are a consequence of increasing MELD scores
and associated comorbidities such as dense portosystemic
encephalopathy, pleural effusions, sarcopenia, and diuretic
refractory fluid retention [14]. While complications increase
the likelihood of a poor outcome, such practice is in line with
the mandates of need based allocation. Numerous studies
have found that select patients with preoperative respiratory
failure could still achieve acceptable long-term outcomes
[3, 15]. The intubated patients in this study, with an average
pretransplant MELD of 32, were eligible if they had FiO
2
≤
40%, positive end-expiratory pressure ≤ 10 cmH
2
O, low
vasopressor requirements, and lack of an active infection.Our
study, with a similarly elevated pretransplant MELD, found
that preoperative respiratory failure was not predictive of
postoperative respiratory failure, supporting the conclusions
found in Knaak et al. These patients were, not surprisingly,
at risk for an increased ICU LOS. Whether a threshold
exists with regard to pretransplant MELD and survival is a
subject of debate as previous investigation has found worse
survival with MELD > 35 [16] while others have associ-
ated increased intensive care utilization but similar survival
[17, 18].
The present study is limited by multicollinearity. Patients
with pronounced left ventricular systolic dysfunction and
more severe obstructive lung disease are excluded from
liver transplant. In addition, these conditions share risk
factors, notably age and smoking, and may coexist in up to
20% of patients [19]. It is unclear that, even with sample
size several times ours, these variables would be powered
enough to be significant in a multivariate logistic regression
analysis.
5. Conclusion
Further research is needed to clarify the relationship between
pre- and postoperative respiratory failure particularly in
the high MELD population. With increasing average pre-
transplant MELD, strategies to optimize respiratory sta-
tus will become more important. Importantly, increased
ICU utilization may alter current patient and provider
expectations for recovery in the immediate postoperative
period.
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